Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
09. Mai 2024 07:15 ET
|
Verona Pharma plc
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at...
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
09. Mai 2024 07:00 ET
|
Verona Pharma plc
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE...
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
02. Mai 2024 02:00 ET
|
Verona Pharma plc
Verona Pharma plc to present additional analyses of positive Phase 3 ENHANCE studies in COPD at ATS 2024.
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
25. April 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first...
Andrew Fisher Joins Verona Pharma as General Counsel
04. März 2024 02:00 ET
|
Verona Pharma plc
Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29. Februar 2024 02:00 ET
|
Verona Pharma plc
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00...
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
15. Februar 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth...
Michael Austwick Joins Verona Pharma as Non-Executive Director
01. Februar 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
03. Januar 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
02. Januar 2024 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”),...